



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/510,148	10/05/2004	Ruoxing Wang	21285-901	6425
47234	7590	09/28/2007	EXAMINER	
LAW OFFICES OF KHALILIAN SIRA, LLC			ZEMAN, ROBERT A	
9100 PERSIMMON TREE ROAD			ART UNIT	PAPER NUMBER
POTOMAC, MD 20854			1645	
MAIL DATE		DELIVERY MODE		
09/28/2007		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/510,148	WANG ET AL.
	Examiner	Art Unit
	Robert A. Zeman	1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 12 July 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-51 is/are pending in the application.
- 4a) Of the above claim(s) 9-15, 20-23 and 25-51 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-6, 16-19, 24 is/are rejected.
- 7) Claim(s) 7 and 8 is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

Applicant's election of Group I in the reply filed on 7-12-2007 is acknowledged.

Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 1-51 are pending. Claims 9-15, 20-23 and 25-51 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Claims 1-8, 16-19 and 24 are currently under examination.

Claim Objections

Claims 2 and 4 are objected for referring to a figure. It is suggested that the claim be rewritten to reference the SEQ ID NO: engendered by said figure.

Claims 7 and 8 are objected to as being dependent on a rejected claim. Said claims would be allowable if presented in independent form.

Claim 24 is objected to because of the following informalities: Said claims recites language drawn to non-elected inventions. Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 5 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 5 is rendered vague and indefinite by the use of the term "physiological conditions" It is unclear to what conditions said term is referring. On what physiology are said conditions being based? The cell? As written, it is impossible to determine the metes and bounds of the claimed invention.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-6, 16-19 and 24 are rejected under 35 U.S.C. 102(b) as being anticipated by Ruben et al. (WO 00/35937).

Ruben et al. disclose an isolated polynucleotide that has 100% sequence identity with SEQ ID NO:1 over at least 500 base pairs (see SEQ ID NO:23 and the alignment set forth below). Said nucleic acid also contains a guanine in position 1 and contains both TATA and CCAATA boxes. Ruben et al. further said nucleic acids can be incorporated into vectors and host

Art Unit: 1645

cells which can be used to recombinantly express the encoded polypeptide (see abstract and claims 7-10) or kits (see page 191, lines 18-20).

Claims 1-6, 16-19 and 24 are rejected under 35 U.S.C. 102(b) as being anticipated by Ruben et al. (U.S. Patent Publication US 2004/0253684).

Ruben et al. disclose an isolated polynucleotide that has 100% sequence identity with SEQ ID NO:1 over at least 500 base pairs (see SEQ ID NO:23 and the alignment set forth below). Said nucleic acid also contains a guanine in position 1 and contains both TATA and CCAATA boxes. Ruben et al. further said nucleic acids can be incorporated into vectors and host cells which can be used to recombinantly express the encoded polypeptide (see abstract and claims 7-10) or kits (see paragraph [0564]).

Qy	8238	GCAGGGGCTTAGATGCTGCTGCGCATCCCTAACCTGTCTGTTCTGTTCTCCTCTGT	8297
Db	8		
Qy	8298	CCCTCCCAGTCTCAGCACTGAGTCTCTGCCATTGGCCTGGTGAGGAAGGAGCTGCC	8357
Db	68		
Qy	8358	AGCCCCACCAAACAGCTCAGGTTACAGAGAGAGTCACTTCTTCATTACTCACAGAGTA	8417
Db	128		
Qy	8418	AACATCAAGGAAGGCCACTGATTGATTGACAGTGTCTGGTCAGATGTCTATCCTAGGC	8477
Db	188		
Qy	8478	CAGTCCCTGTGAACAAGGGATGGGTGTCTGCGTGGACCAGATCTGAACACAGGCCA	8537
Db	248		
Qy	8538	TGCCTGGGCCAGGGTGGAACTATGGACCTCTCCCCACTGAGAACCCAGGGAGC	8597
Db	307		
Qy	8598	AGGTGAGGTGAAATT CCTCTAGGGAAAGAGGGGAAAATTGACAAGATAGCAGATGTCTA	8657
Db	366		

Art Unit: 1645

Qy	8658	CCATACTGCTGGGCCCTGGTCCCTCCCAGAAGGAAAAACATAGTAACAATAGAGTGGG	8717
Db	426	CCATACTGCTGGGCCCTGGTCCCTCCCAGAAGGAAAAACATAGTAACAATAGAGTGGG	485
Qy	8718	TCTCACCCCTCCACCTGGGTCTCAAGTAGGGTGTGGATGAGGACAATGAAATGAAGGAAA	8777
Db	486	TCTCACCCCTCCACCTGGGTCTCAAGTAGGGTGTGGATGAGGACAATGAAATGAAGGAAA	545
Qy	8778	GGTTAGAAGGCCTGTGGTACCGGTTGGTAAATAGCTTCGTGCTTCTCCATATGGAGT	8837
Db	546	GGTTAGAAGGCCTGTGGTACCGGTTGGTAAATAGCTTCGTGCTTCTCCATATGGAGT	605
Qy	8838	GAGAGTCTGGATGTGATTCTTCAAAGTCAGGTCTAGGAGACTCAGGATGCCTAACATCT	8897
Db	606	GAGAGTCTGGATGTGATTCTTCAAAGTCAGGTCTAGGAGACTCAGGATGCCTAACATCT	665
Qy	8898	AGAGGTAAGAACATTGTGAGGAAAGCCAGTGAATTCAAGTCAGTCTTGTCATGCTGACTTTGAA	8957
Db	666	AGAGGTAAGAACATTGTGAGGAAAGCCAGTGAATTCAAGTCAGTCTTGTCATGCTGACTTTGAA	725
Qy	8958	GTACTTTGGAAGAGCCAAGTGAATTATCCACAGGACAGGACCAAATCTTACCTGGTTC	9017
Db	726	GTACTTTGGAAGAGCCAAGTGAATTATCCACAGGACAGGACCAAATCTTACCTGGTTC	785
Qy	9018	TTCCCCAGGCCACTAGTCACAACAGGAAATAAAAGAGTTGCCCGATACCAAGGTGT	9077
Db	786	TTCCCCAGGCCACTAGTCACAACAGGAAATAAAAGAGTTGCCCGATACCAAGGTGT	845
Qy	9078	ACTAGTCCATTCTCACACTGCTATGGGAAATACCTGAGACTGGTAATTATAAGGGA	9137
Db	846	ACTAGTCCATTCTCACACTGCTATGGGAAATACCTGAGACTGGTAATTATAAGGGA	905
Qy	9138	AAAGGTTTAATTGACTCACAGTTCTAGATGGCTGGGGAGGCTTCAGGAAACTAACATCA	9197
Db	906	AAAGGTTTAATTGACTCACAGTTCTAGATGGCTGGGGAGGCTTCAGGAAACTAACATCA	965
Qy	9198	TGGCAGAAGGCACCACCTCACAGGGTGGCGGGAGAGAGAATGAGTGCCAGCGAAGGGAG	9257
Db	966	TGGCAGAAGGCACCACCTCACAGGGTGGCGGGAGAGAGAATGAGTGCCAGCGAAGGGAG	1025
Qy	9258	AAGCTCCTTATAAAACCATCTGTTCTCCTTATAAGATCTCTTAATAAAACCGTCAGAGA	9317
Db	1026	AAGCTCCTTATAAAACCATCTGTTCTCCTTATAAGATCTCTTAATAAAACCGTCAGAGA	1085
Qy	9318	ACTATCTCATTCACTATCAGGAGAACAGCATGGGGAACGCCCCCATGATTCAAGTTAC	9377
Db	1086	ACTATCTCATTCACTATCAGGAGAACAGCATGGGGAACGCCCCCATGATTCAAGTTAC	1145
Qy	9378	TCCACCTGGTCCGCCCTTGACATGTGGGTGTTATTACAATTAAAGGTGAGATTGGTG	9437
Db	1146	TCCACCTGGTCCGCCCTTGACATGTGGGTGTTATTACAATTAAAGGTGAGATTGGTG	1205
Qy	9438	GGGACACAGAGCCAAACCATATCACAAAGGCTTCTCCTCCTGGTGGATTGTACCCATA	9497
Db	1206	GGGACACAGAGCCAAACCATATCACAAAGGCTTCTCCTCCTGGTGGATTGTACCCATA	1265
Qy	9498	GCCTCTTCTGAGTCCTCTCTTTAGCCTCTTATGCCTGCAGTGCATCCTTATACCA	9557
Db	1266	GCCTCTTCTGAGTCCTCTCTTTAGCCTCTTATGCCTGCAGTGCATCCTTATACCA	1325

Art Unit: 1645

Qy	9558	TTTCTAGAGTCATCTTATAAAACTTAACTCTCCGTATGACTCATAAATCCTGTTTTT	9617
Db	1326	TTTCTAGAGTCATCTTATAAAACTTAACTCTCCGTATGACTCATAAATCCTGTTTTT	1385
Qy	9618	TTTTGCACAGTATATTAAAGTATAAAATTGTTAAAGTCTTTAATGGCTGCCCCAAGC	9677
Db	1386	TTTTGCACAGTATATTAAAGTAT-AAATTGTTAAAGTCTTTAATGGCTGCCCCAAGC	1444
Qy	9678	TACATTTCCATTGTTGATGCTTCAGTTCTTCACTTTGATTTGGCTGTTGAGTTA	9737
Db	1445	TACATTTCCATTGTTGATGCTTCAGTTCTTCACTTTGATTTGGCTGTTGAGTTA	1504
Qy	9738	ACTGAATTTTGCCATTCCATTAACCCATCCCAGCTTTCCCACCTCTAGATTTCACTT	9797
Db	1505	ACTGAATTTTGCCATTCCATTAACCCATCCCAGCTTTCCCACCTCTAGATTTCACTT	1564
Qy	9798	TTCTTGTAGGCTAGAATGCTTGACTGGGATCTGACTGGAGATAATGAGAACAAAAACTG	9857
Db	1565	TTCTTGTAGGCTAGAATGCTTGACTGGGATCTGACTGGAGATAATGAGAACAAAAACTG	1624
Qy	9858	GTTCAAAGAGCCAGGATGTTGCATAAAAGCTCTAACAGATTGATCTAACAGGTAAAATAA	9917
Db	1625	GTTCAAAGAGCCAGGATGTTGCATAAAAGCTCTAACAGATTGATCTAACAGGTAAAATAA	1684
Qy	9918	AAATTAGGCAATTACTAAATTGAAATGCTCACATTATTAAATAAGGCATGTAACAT	9977
Db	1685	AAATTAGGCAATTACTAAATTGAAATGCTCACATTATTAAATAAGGCATGTAACAT	1744
Qy	9978	CTACATGAGCCATCATTGCTTTTAATTCCACATTGATTAGGAGCCAAACCTTCAGGG	10037
Db	1745	CTACATGAGCCATCATTGCTTTTAATTCCACATTGATTAGGAGCCAAACCTTCAGGG	1804
Qy	10038	CAGGTATCCGGTAGAGCGCCCTGGAGAGGCCCTGGATAGGCACAGGCGCTGTCAGGGGG	10097
Db	1805	CAGGTATCCGGTAGAGCGCCCTGGAGAGGCCCTGGATAGGCACAGGCGCTGTCAGGGGG	1864
Qy	10098	CTCTCACATGCTGTGCTGCTGCTGGAGAGAGGGGGCCAGAGACTAGGGGGCTTCT	10157
Db	1865	CTCTCACATGCTGTGCTGCTGCTGGAGAGAGGGGGCCAGAGACTAGGGGGCTTCT	1924
Qy	10158	AAGAAGAGGTGGCATTCTGCTCAGTGTGAAGGATGAATAACCTTGACAGGCTGGAAA	10217
Db	1925	AAGAAGAGGTGGCATTCTGCTCAGTGTGAAGGATGAATAACCTTGACAGGCTGGAAA	1984
Qy	10218	AAGGTGACATTCAGGTAGAGCGTGTACATGGATGTAACATACCAAGGTCAAGGACATG	10277
Db	1985	AAGGTGACATTCAGGTAGAGCGTGTACATGGATGTAACATACCAAGGTCAAGGACATG	2044
Qy	10278	GGCTTGAGAGATGGTGAGAAGGATGGAGGTGACTGTGGCTTGCAATTCTATCCGTATCACT	10337
Db	2045	GGCTTGAGAGATGGTGAGAAGGATGGAGGTGACTGTGGCTTGCAATTCTATCCGTATCACT	2104
Qy	10338	ATTAATTACCTCTAACGCTTGGCTAGGTGGTGGACAAGTAAAGTAATGGACAAA	10397
Db	2105	ATTAATTACCTCTAACGCTTGGCTAGGTGGTGGACAAGTAAAGTAATGGACAAA	2164
Qy	10398	TACTTTCTACCAATATTAGTGACCAAATGCAGAGTTATGGAGAGGGCCAGGGACCTC	10457
Db	2165	TACTTTCTACCAATATTAGTGACCAAATGCAGAGTTATGGAGAGGGCCAGGGACCTC	2224

Art Unit: 1645

Qy	10458	ATGAACCATACTCTTCTAGTCTAGGGACATAACTCCAATGCCTTCCTGTCCCAGTAAG	10517
Db	2225	ATGAACCATACTCTTCTAGTCTAGGGACATAACTCCAATGCCTTCCTGTCCCAGTAAG	2284
Qy	10518	AGGCCATGGATTCAAGAACGCCAGACAATCCATTCTTCAGATAATGATAAAAAAGAAC	10577
Db	2285	AGGCCATGGATTCAAGAACGCCAGACAATCCATTCTTCAGATAATGATAAAAAAGAAC	2344
Qy	10578	CATTATTTATTTCTAAGTATAGAATGAAACATTATAGTTGCCAAATTTGGTACCT	10637
Db	2345	CATTATTTATTTCTAAGTATAGAATGAAACATTATAGTTGCCAAATTTGGTACCT	2404
Qy	10638	TTTAGGAGAAAATACAGATTTTTGTTAAAAATAAACCTAAAAA	10697
Db	2405	TTTAGGAGAAAATACAGATTTTTGTTAAAAATAAACCTAAAAA	2464
Qy	10698	GA 10699	
Db	2465	AA 2466	

Conclusion

No claim is allowed.

SEQ ID NO:1 (full length) is free of the art of record.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866.

The examiner can normally be reached on Monday- Thursday, 7am -5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on (571) 272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



ROBERT A. ZEMAN
PRIMARY EXAMINER

September 25, 2007